Essa Pharma Merges with XenoTherapeutics to Enhance Prostate Cancer Treatment Innovations
- Essa Pharma has been acquired by XenoTherapeutics, enhancing its capabilities in prostate cancer treatment development.
- Shareholders of Essa Pharma will receive contingent value rights, potentially totaling around US$6.7 million.
- Essa Pharma will delist from Nasdaq and align closely with XenoTherapeutics' research focus post-acquisition.
Essa Pharma Joins Forces with XenoTherapeutics: A New Chapter in Prostate Cancer Treatment
Essa Pharma Inc., a pharmaceutical company renowned for its innovative therapies targeting prostate cancer, has recently completed its acquisition by XenoTherapeutics, Inc. This strategic move marks a significant development in the landscape of cancer treatment research and development. The acquisition was executed through Xeno Acquisition Corp., a wholly owned subsidiary of XenoTherapeutics, which acquired all outstanding common shares of Essa for approximately US$0.1242 per share. In addition, Essa shareholders are set to receive a contingent value right (CVR) for each share, allowing for potential additional payments up to US$0.14 per CVR, contingent on specific liabilities. This could lead to an aggregate distribution of around US$6.7 million, highlighting the financial incentives tied to this acquisition.
The decision to merge with XenoTherapeutics underscores a growing interest in innovative therapeutic solutions, particularly in the field of oncology. With XenoTherapeutics’ focus on xenotransplantation and its commitment to advancing scientific research, this acquisition is poised to enhance Essa Pharma's capabilities in developing novel prostate cancer treatments. The Supreme Court of British Columbia has provided its final approval for the acquisition, which took place on October 7, 2025. Following this approval, Essa has initiated the process to delist its shares from the Nasdaq Capital Market and will terminate its registration under the U.S. Securities Exchange Act of 1934 approximately 10 days after the acquisition's closure. This strategic shift allows Essa to align more closely with XenoTherapeutics' vision and resources.
As Essa Pharma transitions into this new phase, the collaboration promises to bring forth advancements in therapeutic options for prostate cancer, a condition that remains a significant health concern worldwide. By merging with XenoTherapeutics, Essa can leverage its new partner's research foundation to enhance clinical development and public education surrounding prostate cancer treatments. The synergy between the two companies is expected to accelerate the pace of innovation in this critical area of healthcare, potentially leading to improved patient outcomes and expanding treatment options for those affected by prostate cancer.
In addition to the acquisition details, it is noteworthy that Leerink Partners LLC acted as the exclusive financial advisor for Essa Pharma during this process, while legal counsel was provided by Blake, Cassels & Graydon, LLP in Canada and Skadden, Arps, Slate, Meagher & Flom LLP in the U.S. This robust advisory framework reflects the complexity and significance of the transaction, ensuring that Essa’s transition into the XenoTherapeutics family is both strategic and legally sound.
For further insights on Essa Pharma’s developments and XenoTherapeutics’ mission, interested parties can visit their respective websites at www.essapharma.com and www.xenotx.org.